Morgan Stanley Cuts GILD Price Target to $168 After Earnings
The firm lowered its outlook on Gilead Sciences following first-quarter results while maintaining an Overweight rating on the stock. Morgan Stanley reduced its price target for Gilead Sciences (NASDAQ:GILD) to $168 from $175 after the company’s first-quarter earnings repor